Fig. 1 · Structure
Documents & Downloads
Zeteletinib
RET Kinase Inhibitor
Zeteletinib is a selective RET kinase inhibitor that demonstrates exceptional potency against wild type RET and RETV804M/L gatekeeper mutants, as well as the frequently encountered oncogenic mutation M918T. This orally active compound exhibits nanomolar affinity for RET while maintaining over 300-fold selectivity for VEGFR2. Zeteletinib is recognized for its robust antitumor activity, making it a valuable tool in cancer research and therapeutic development focused on RET-driven malignancies.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| Actions | Inhibitor |
| CAS Number | 2216753-97-6 |
| Applications | RET Kinase Inhibitor |
| Formula | C25H23F3N4O4 |
| Molecular Weight | 500.47 |
| Synonyms | BOS-172738; DS-5010 |
| SMILES | O=C(CC1=CC=C(C2=CN=C3C=C(C(OC)=CC3=C2)OC)N=C1)NC4=CC(C(C)(C(F)(F)F)C)=NO4 |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.